Document is current

Article History

Received: 31 July 2017

Accepted: 23 May 2018

First Online: 2 July 2018

Ethics approval and consent to participate

: De-identified rsEEG data were obtained from Boston Children’s Hospital, Harvard Medical School, Boston, USA. These data were a clinical collection of EEG’s for a protocol entitled, “Risk factors for poor outcome in tuberous sclerosis”. IRB/ethics approval at the host institute included a ‘waiver of consent’ to allow sharing of data with collaborators without seeking further consent from participants. Participants therefore consented to ‘de-identified’ data being used. Data collection and analysis for this study had already been completed, and results were published by Peters et al. [ CitationRef removed ]. Ethics approval for the secondary analysis of this data was obtained from both Tygerberg Health Research Ethics Committee (reference # S14/06/128) and the University of Cape Town Human Research Ethics Committee (reference # 865/2014).

: CA, JMP, SSJ, MS and PJdV report no conflicts of interest in relation to the work presented here. TH was the developer of the RQA biomarker method [ CitationRef removed ]. However, she does not have any financial conflicts of interest in relation to the method, which was published in an open-access, peer-reviewed publication [ CitationRef removed ].

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.